

Area Drugs and Therapeutics Committee Meeting Minutes

Wednesday 18th June 2025 10-12.30pm

Microsoft Teams Meeting

	Present					
	Graeme Bryson (Acting Chair)		Victoria Gemmell (Prof Sec)			
	Veronica Rainey		Gail Richardson			
	Rachael Kelly		Kirsty MacFarlane			
	Chris Miller		Eimear Gordon			
	Craig Thurtell		Stephanie Dundas (until item 8j)			
	David Semple (until item 8i)		Emma Harris (item 8L)			
	Scott Hamilton (Item 8b, c)		Tyra Smyth			
	Christine Carswell (until item 8a)					
1.	Apologies					
	Sharon Murray, Penny Brankin, Alastair Brown, Colin Angus, Kelly Baillie					
2.	Declaration of Interest					
	Nil					
3.	Ratification of minutes of April 2025 meeting					
	These were agreed as a true reflection of the meeting and can be published.					
4.	Matters arising not covered elsewhere on the agenda					
a.	Hyperacute Stroke – Alteplase Guidance for Patients Requiring Thrombolysis – Alternative to Tenecteplase – Mark Barber / Gary Lynas– Update awaited					
b.	Use of Insulin Pump Systems in Acute Hospitals – Elizabeth McIntyre– Update awaited					
c.	Lebrikizumab – Carol Martin– Update awaited It was noted at the previous meeting, one of the conditions attached to the approval for the use of lebrikizumab was the submission and approval of a corresponding treatment pathway. To date, this has not yet been received. A reminder will be issued to clarify that lebrikizumab is not approved for use until the required treatment pathway has been submitted and formally approved.					
d.	Matters Arising – Query Medicines of Low Clinical Value – Feedback CM Covered under item 8L.					
5.	ADTC Committee Business					
a.	Welcome of new ADTC chair Veronica Rainey.					
b.	Draft ToR – Graeme Bryson GRB presented a draft ToR. The document will be circulated for comment from the membership. There was discussion around importance of interplay and communication with key groups. Additional GP involvement was suggested.					
6.	SMC Advice - CONFIDENTIAL					
6.1.a	FULL SUBMISSION					
	Medicine	Manufacturer	Indication in brief	SMC reference	Advice Summary	
	fezolinetant (Veoza)	Astellas Pharma Ltd	For the treatment of moderate to severe vasomotor	SMC2798	NOT RECOMMENDED	

			symptoms (VMS) associated with menopause.			
	amivantamab concentrate for solution for infusion (Rybrevant)	Janssen-Cilag Ltd	In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon20 insertion mutations.	SMC2758	NOT RECOMMENDED	
	osimertinib (Tagrisso)	AstraZeneca	In combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.	SMC2736	ACCEPTED with PAS	
	sepercatinib hard capsules (Retsevmo)	Eli Lilly and Company	As monotherapy for the treatment of adults and adolescents 12 years and older with advanced <i>RET</i> fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).	SMC2733	ACCEPTED RESTRICTED with PAS	

abaloparatide solution for injection in pre-filled pen (Eladynos®)	Theramex	Treatment of osteoporosis in postmenopausal women at increased risk of fracture.	SMC2764	ACCEPTED RESTRICTED with PAS
pembrolizumab concentrate for solution for infusion (Keytruda®)	Merck Sharp & Dohme (UK) Limited	In combination with carboplatin and paclitaxel, for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults.	SMC2767	ACCEPTED with PAS

6.1.b

RESUBMISSION

Medicine	Manufacturer	Indication in brief	SMC reference	Advice Summary
lecanemab (Leqembi)	Eisai Ltd	For the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ε 4 (ApoEε4) heterozygotes or non-carriers.	SMC2811	NOT RECOMMENDED

6.1.c

Deferred Advice

bevacizumab gamma (Lytenava) Outlook Therapeutics Limited SMC2744

6.1.d

Amended Advice

cladribine 10mg tablet (Mavenclad) Merck SMC2751

selpercatinib hard capsules (Retsevmo) (MTC) Eli Lilly and Company Limited SMC2732

These were noted.

6.1.e

ABBREVIATED SUBMISSION

<p>6.1.f</p> <p>6.1.g</p> <p>6.1.h</p> <p>6.1.i</p> <p>6.1.j</p>	<p>Nil</p> <p><u>NON SUBMISSIONS</u></p> <p>Nil</p> <p><u>WITHHELD</u></p> <p>Nil</p> <p><u>Paediatric License Extensions</u></p> <p>Nil</p> <p>Collaborative Advice</p> <p>Nil</p> <p>Ultra Orphan Update</p> <p>Nil</p>	
<p>6.2</p>	<p>Updates to NHS LK status on SMC advice</p> <p><u>Follow up</u></p> <p>RK presented the follow up and fed back to the committee about requests sent post ADTC (May 25). This included Ruxolitinib, of which the ADTC will look to WOSCan to inform local designation. Caldribine was discussed and updated designation agreed. Designations for Symbicort turbobaler, rezafungin, lebrikizumab were updated in line with papers presented at previous ADTC to being available. It is understood that a comprehensive treatment pathway is still expected for lebrikizumab from dermatology.</p> <p><u>Bulletins</u></p> <p>RK presented updated bulletins which contain designation updates as discussed in other areas of the agenda, which were agreed and will be published on the RDS site via the normal process.</p>	
<p>7.</p>	<p>Lanarkshire Formulary / West of Scotland Formulary</p>	
<p>7.1.a</p>	<p>NHSLK formulary changes proposals</p> <p>Proposed formulary amendments</p> <p>-Comprises of updates to remove out of date notes on the formulary, and discontinued products following discussions with consultants in the area. Also a proposal to remove bullet points relating to specific brands of macrogol osmotic laxative sachets to align with advice around branded generic prescribing and to align with the SDT. These were agreed.</p>	
<p>7.2</p>	<p>West of Scotland Formulary Updates</p> <p>VG presented the draft versions of forms that will be utilised by all 5 Boards when considering inclusion to the WRF. Please send any comments which will be fed back to the regional team.</p> <p>Chapter expert groups for GI and Cardiovascular have been formalised and work will begin from July. It is hoped that ongoing discussions will see more GP nominations.</p>	
<p>8.</p>	<p>Clinical Protocols & Guidelines</p>	
<p>a.</p>	<p>Adult Non Obstetric Major Haemorrhage – Andrew Fyfe</p> <p>This is an update to current guidance. Some points of clarification were raised which will be fed back to the author.</p> <p>The document was not approved at this time.</p>	

	<p>b. Alcohol Withdrawal Guidance – Lorna Templeton This is an update to current guidance. Alterations were necessary due to changes with supplies of IV vitamins. The team took this opportunity to add a HEPMA guide and transfer over to the standard template. The document was approved subject to minor amendments.</p> <p>c. Clozapine-Induced Gastrointestinal Hypomotility Guidance – Lorna Templeton This is an update to current guidance. Changes include update in line with changes to MORSE and addition of appendices regarding lifestyle advice and stool chart. The document was approved subject to minor amendments.</p> <p>The committee noted that both MH documents have been well designed and are clear to follow, with good collaboration and governance process.</p> <p>d. Major Haemorrhage Protocol for Paediatric Patients– Christopher Moultrie This was approved with no changes.</p> <p>e. NHSL COPD Treatment Guide – Manish Patel This was small update to recently approved guidance. The change included a move from red to green for the carbon footprint of Trixeo inhaler. The document was approved subject to minor amendments.</p> <p>f. Produodopa Clinical Protocol – Dawn Henderson The committee were satisfied with the clinical content of the protocol. However, some points remain outstanding on operational implementation, including supply via Homecare and governance around use of industry staff to train patients. Eimear Gordon has kindly offered to provide support with implementation. This document is approved subject to engagement with the pharmacy team.</p> <p>g. Serotonin Syndrome Adult Guideline – Sarah Brady This is an update to current guidance. The document was not approved at this time.</p> <p>h. SGLT2i for Treatment of Chronic Kidney Disease Guidance – Alison Yule This is an update to current guidance. Changes include incorporation of new SMC advice for dapagliflozin. The document was approved subject to minor amendments</p> <p>i. Subcutaneous Oxycodone Analgesia Protocol - Colum Slorach The committee had several comments around both the clinical content and operational aspects. These will be fed back to the author. In addition, a suggestion was made to share the concerns with the AMMB Chair to take forward. The document was not approved at this time.</p> <p>j. Medicines Monitoring Drug Specific Documents – Kirsty MacFarlane KM gave a summary of the purpose and function of the documents. They were developed in partnership with a wide range of stakeholders. A query was raised in relation to lithium monitoring. Additional clarification on an operational aspect is required before the lithium guidance can be approved. The other documents were approved with a 12-month review date.</p>	
--	---	--

	<p>k. Refeeding Guidelines Submission – Pamela Miller This is an update to current guidance. The document was approved subject to minor amendment.</p> <p>l. Medicines of Low Therapeutic Value This is an update to a previous version. Key changes include alignment with National guidance, updates to specific indications, addition of a feedback form. With reference to item 4d, EH discussed that while practices may signpost patients to purchase items, it does not preclude prescription for specific specialist recommendations. There was discussion around the need for inclusion of a list of specific exclusions, however the committee felt on balance that the current exclusion for simeticone was adequate, and further exclusions would not be helpful. There was a request to link in with HEPMA team to utilize a technical solution to support the guideline and to include AMMB and PMMB to ensure wide dissemination. The document was approved with no changes.</p>	
9.	New Medicine Safety Notifications & Alerts	GR B
	<p>a. CAS - Home nil</p> <p>b. MHRA Updates – Medicines Safety Roundup May 2025 https://www.gov.uk/drug-safety-update This was noted</p> <p>c. GLP-1 medicines for weight loss and diabetes: what you need to know - GOV.UK This was noted</p> <p>d. NPSA Promixin Feedback – Victoria Gemmell VG gave feedback as previously requested. The committee agreed that actions taken were adequate.</p> <p>e. Medicines Related Communications to Health Boards – Graeme Bryson</p>	
10.	Prescribing Management Board Update	
	Nil	
11.	Medicines for the Treatment of Cancer	
	Nil	
12.	Non-Medical Prescribing	
	Nil	
13.	PGD Activity Report	
	<p>This is new report which will be provided by the Medicines Guidance team on an ongoing basis. The purpose is to ensure the committee is kept up to date on the current Board position on PGD's, and raise any issues. Work is ongoing reviewing the previous PGD process which will be fed back to the Committee in due course.</p>	
14.	Antimicrobial Management Team Update	

	Nil	
15.	Lay member related items	
	Nil	
16.	AOCB	
a.	ULM Request - Omalizumab – Carole Martin As the treatment indication was stated as urticaria, a concern was raised regarding the potential for widespread use. The committee felt that individual patient requests may be more appropriate. Financial approval was not completed. The committee did not feel there was enough information to approve this The request WAS NOT approved.	
b.	ULM Request - Triamcinolone (Dermatology) - Carole Martin This was approved. This approval will expire in 12 months	
c.	ULM Request – Triamcinolone (Rheumatology) – Hannah Rae This was approved. This approval will expire in 12 months	
d.	Clarifications in Relation to Vifor Pharma’s Communications about Monofer in the UK – Graeme Bryson This was noted.	
e.	ADTC Collaborative Draft Terms of Reference Request for any comments can be sent to adtc mailbox.	
17.	Date of next meeting	
	Wednesday 23 rd July 2025 10-12.30pm MS TEAMS	